Topics:
Head and Neck Cancers • Radiation Oncology
Are you using the commercially available Naveris assay for HPV+ OPX cancers in your practice?
Based on the JCO 2020 paper, how are you using this information?
I understand there is no data to change management and most of us will be hesitant to do so at this point. But can this help to change the frequency/modality of surveillance?
Answer from: Radiation Oncologist at Academic Institution
Our practice at Emory is to get this at initial consult for all HPV+ oropharyngeal cancers so that we can establish if ctHPVDNA is positive (as it is not positive in all HPV+ cases).
Right now, I find it most useful at the three month scan in equivocal cases, a negative ctHPVDNA leads us more...
Sign in or Register to read more